DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Vincent-Viry, M.
Right arrow Articles by Galteau, M.-M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Vincent-Viry, M.
Right arrow Articles by Galteau, M.-M.

Vol. 28, Issue 6, 617-619, June 2000

SHORT COMMUNICATION
Short Communication
The Effects of Drinking and Smoking on the CYP2D6 Metabolic Capacity

Monique Vincent-Viry, Blandine Fournier, and Marie-Madeleine Galteau

Laboratoire du Centre de
Médecine Préventive
(M.V.-V., M.M.G.),
Département Statistiques
du Centre de Médecine
Préventive (B.F.),
54501 Vandoeuvre-lès-Nancy
Cédex, France,
EA 3117 Université
Henri Poincaré Nancy 1 (M.M.G.),
Centre du Médicament,
54000 Nancy, France

We studied the influence of drinking and smoking habits on CYP2D6 metabolic capacity measured by the use of debrisoquine as a substance test. We did not find any significant differences in the frequency of subjects with CYP2D6 deficiency (poor metabolizers) among four groups of healthy individuals: nonsmokers/nondrinkers, smokers/drinkers, nondrinkers/smokers, and nonsmokers/drinkers. We demonstrated that, among poor metabolizers, alcohol and tobacco consumption was associated with higher metabolic ratios than it was with the control group, but the differences were not statistically significant. Among extensive metabolizers, the lowest metabolic ratio (highest enzyme activity) was detected for nondrinkers/smokers, intermediate values for smokers/drinkers, and the highest metabolic ratio (lowest enzyme activity) for nonsmokers/drinkers. These variations were slight but statistically significant when logarithmic ratio values were applied. These results show that smoking and drinking habits do not need to be taken into account when humans are phenotyped for CYP2D6.


Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Drug Metab. Dispos.Home page
Y. Zhen, O. Slanar, K. W. Krausz, C. Chen, J. Slavik, K. L. McPhail, T. M. Zabriskie, F. Perlik, F. J. Gonzalez, and J. R. Idle
3,4-Dehydrodebrisoquine, a Novel Debrisoquine Metabolite Formed from 4-Hydroxydebrisoquine That Affects the CYP2D6 Metabolic Ratio
Drug Metab. Dispos., September 1, 2006; 34(9): 1563 - 1574.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
H. Payami, N. Lee, S. Zareparsi, M. Gonzales McNeal, R. Camicioli, T.D. Bird, G. Sexton, S. Gancher, J. Kaye, D. Calhoun, et al.
Parkinson's disease, CYP2D6 polymorphism, and age
Neurology, May 22, 2001; 56(10): 1363 - 1370.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.